Parallel Advisors’s Adverum Biotechnologies ADVM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-50
| Closed | -$227 | – | 3622 |
|
|
2025
Q3 | $227 | Hold |
50
| – | – | ﹤0.01% | 3431 |
|
|
2025
Q2 | $108 | Hold |
50
| – | – | ﹤0.01% | 3458 |
|
|
2025
Q1 | $219 | Hold |
50
| – | – | ﹤0.01% | 3367 |
|
|
2024
Q4 | $234 | Hold |
50
| – | – | ﹤0.01% | 3354 |
|
|
2024
Q3 | $351 | Hold |
50
| – | – | ﹤0.01% | 3225 |
|
|
2024
Q2 | $343 | Hold |
50
| – | – | ﹤0.01% | 3141 |
|
|
2024
Q1 | $707 | Hold |
50
| – | – | ﹤0.01% | 2997 |
|
|
2023
Q4 | $376 | Sell |
50
-50
| -50% | -$456 | ﹤0.01% | 3099 |
|
|
2023
Q3 | $1.5K | Hold |
100
| – | – | ﹤0.01% | 2892 |
|
|
2023
Q2 | $1.59K | Hold |
100
| – | – | ﹤0.01% | 2818 |
|
|
2023
Q1 | $717 | Hold |
100
| – | – | ﹤0.01% | 3026 |
|
|
2022
Q4 | $580 | Hold |
100
| – | – | ﹤0.01% | 3008 |
|
|
2022
Q3 | $1K | Hold |
100
| – | – | ﹤0.01% | 2830 |
|
|
2022
Q2 | $1K | Hold |
100
| – | – | ﹤0.01% | 2686 |
|
|
2022
Q1 | $1K | Hold |
100
| – | – | ﹤0.01% | 2673 |
|
|
2021
Q4 | $2K | Hold |
100
| – | – | ﹤0.01% | 2646 |
|
|
2021
Q3 | $2K | Sell |
100
-2,411
| -96% | -$61.5K | ﹤0.01% | 2635 |
|
|
2021
Q2 | $88K | Buy |
2,511
+27
| +1% | +$1.45K | ﹤0.01% | 993 |
|
|
2021
Q1 | $245K | Sell |
2,484
-2,383
| -49% | -$286K | 0.01% | 569 |
|
|
2020
Q4 | $528K | Hold |
4,867
| – | – | 0.03% | 317 |
|
|
2020
Q3 | $501K | Buy |
4,867
+96
| +2% | +$14.4K | 0.03% | 304 |
|
|
2020
Q2 | $996K | Sell |
4,771
-995
| -17% | -$176K | 0.07% | 178 |
|
|
2020
Q1 | $563K | Buy |
+5,766
| New | +$672K | 0.05% | 222 |
|
Parallel Advisors's ADVM Position: Q4 2025 in Review
Parallel Advisors sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 50 shares — an estimated $227 sold.
Parallel Advisors first reported a position in ADVM in Q1 2020 and held it in 23 quarters. The position peaked at $996K in Q2 2020. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.
- Parallel Advisors reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
- Parallel Advisors sold 50 Adverum Biotechnologies shares in Q4 2025, an estimated $227.
- Parallel Advisors first reported a position in Adverum Biotechnologies in Q1 2020 and held it in 23 quarters.
- Parallel Advisors's Adverum Biotechnologies position peaked at $996K in Q2 2020.
- 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.
Based on Parallel Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.